2024/08/07 08:59:59 | |
---|---|
Price | |
0.729 EUR | |
Difference | 2.21% (0.02) |
ISIN | NL0010391025 |
Symbol | PHARM |
Exchange | London Stock Exchange European Trade Reporting |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 487 EUR |
Benchmark | AMSTERDAM EXCHANGES INDEX |
Bid (Bid size) | 0.7295 EUR (75,000) |
Ask (Ask size) | 0.7665 EUR (75,000) |
Open | 0.729 EUR |
High | 0.729 EUR |
Low | 0.729 EUR |
Close (prev. day) | 0.7133 EUR |
VWAP | 0.7621 EUR |
Volume (pcs) | - |
Trading volume | - |
Number of trades | 1 |
Last size | - |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/07/24 | Global Equity Ratings | ||
2024/07/12 | Global Equity Ratings | ||
2024/06/21 | Global Equity Ratings | ||
2024/06/14 | Global Equity Ratings | ||
2024/05/29 | Global Equity Ratings |
2024/08/07 08:59:59 | |
---|---|
Price | |
0.729 EUR | |
Difference | 2.21% (0.02) |
ISIN | NL0010391025 |
Symbol | PHARM |
Exchange | London Stock Exchange European Trade Reporting |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 487 EUR |
Benchmark | AMSTERDAM EXCHANGES INDEX |
Bid (Bid size) | 0.7295 EUR (75,000) |
Ask (Ask size) | 0.7665 EUR (75,000) |
Open | 0.729 EUR |
High | 0.729 EUR |
Low | 0.729 EUR |
Close (prev. day) | 0.7133 EUR |
VWAP | 0.7621 EUR |
Volume (pcs) | - |
Trading volume | - |
Number of trades | 1 |
Last size | - |
6m | 1Y | 3Y | |
Perf (%) | -36.49% | -37.46% | -22.76% |
Perf (abs.) | -0.41 | -0.43 | -0.21 |
Beta | 1.29 | 0.98 | 0.82 |
Volatility | 33.87 | 32.89 | 41.05 |
Ø price 5 days | Ø volume 5 days (pcs.) | 0.731 EUR (0) |
Ø price 30 days | Ø volume 30 days (pcs.) | 0.764 EUR (0) |
Ø price 100 days | Ø volume 100 days (pcs.) | 0.851 EUR (1) |
Ø price 250 days | Ø volume 250 days (pcs.) | 1.006 EUR (16,457) |
YTD High | date | 1.200 EUR (2024/01/10) |
YTD Low | date | 0.682 EUR (2024/08/05) |
52 Weeks High | date | 1.299 EUR (2023/09/18) |
52 Weeks Low | date | 0.682 EUR (2024/08/05) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/08/07 | 17:05 | 0.742 EUR | 0.01 | 22 |
Stuttgart | 2024/08/07 | 16:25 | 0.743 EUR | 0.00 | 9 |
Munich | 2024/08/07 | 08:18 | 0.702 EUR | 0.00 | 1 |
London Stock Exchange European Trade Reporting | 2024/08/07 | 08:59 | 0.729 EUR | 0.00 | 1 |
Frankfurt | 2024/08/07 | 08:08 | 0.71 EUR | 0.00 | 1 |
FINRA other OTC Issues | 2024/08/06 | 21:59 | 0.75 USD | 0.00 | 1 |
Euronext Amsterdam | 2024/08/07 | 17:05 | 0.74 EUR | 3.53 | 1,137 |
Duesseldorf | 2024/08/07 | 08:10 | 0.7025 EUR | 0.00 | 1 |
Berlin | 2024/08/07 | 08:18 | 0.7035 EUR | 0.00 | 1 |
PHARMING GROUP NV |
- - |
Darwinweg 24 - 2333 CR Leiden |
Telefon: +31-71-524-74-00 |
Fax: + |
E-mail: info@pharming.com |
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands. |
Sijmen de Vries | Chairman of Managing Board |
Alexander Breidenbach | Member of Executive Committee |
Anurag Relan | Member of Executive Committee |
Jeroen Wakkerman | Member of Executive Committee |
Mireille Sanders | Member of Executive Committee |
Ruud van Outersterp | Member of Executive Committee |
Stephen Toor | Member of Executive Committee |
Richard Peters | Chairman of Supervisory Board |
Jabine T. M. van der Meijs | Member of Supervisory Board |
Mark Pykett | Member of Supervisory Board |
Barbara Yanni | Member of Supervisory Board |
Deborah Jorn | Member of Supervisory Board |
Leonard Kruimer | Member of Supervisory Board |
Steven Baert | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer